Back to School: How biopharma can reboot drug development. Access exclusive analysis here
LLY suspended enrollment in a pair of Phase II trials of prasugrel based on preliminary pharmacokinetic data that
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury